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chem 700 and in the Cobas Bio analyzer, the latter with
reagents from the S.V.R Enzymatic Triglyceride Kit (cat.
no. 869103; Bebring Diagnostics, La Jolla, CA 92037). The
original patient’s sample proved to have a triglyceride
concentration of 79.4 mmoL’L.
The Ektachem results obtained up to 6.63 mmolfL were
not flagged; concentrations between 6.63 and 60 mmol/L
were flagged either with a> sign or “no result”; however, at
concentrations above 60 mmol/L results <6.63 mmol/L were
reported. The results clearly demonstrated that samples
with triglyceride concentrations >60 mmoIfL may potential-
ly give spuriously low results when analyzed in the Ekta-
diem.
Experienced laboratory staff will recognize that such
results are inconsistent with the specimen’s appearance.
However, with the advent of this system, in particular the
Kodak DT6O system, more and more non-laboratory staff
members are operating these systems (1). In such cases, the
spurious result may not be recognized, and consequent
treatment may be inadequate or inappropriate.
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In an immunoradiometric assay (nu) for lutropin (lu-
teinizing hormone, LH) recently developed by RSIJJmmun-
chem Corp., Carson, CA, specific monoclonal antibodies
directed against two distinct immunogenic sites of the LH
molecule are used. The assay is used primarily to detect the
preovulatory rise and peak of LH in serum as a predictor of
ovulation time in women.
The usual way of detecting preovulatory serum UI is
traditional RIA with a single ligand. Reports comparing
results for serum UI by traditional RIA with those for
urinary UI by enzyme-linked immunosorbent assay (ELI8A),
however, indicate differences in time and duration of the LII
peak (1). Because the UI species detected by the RIA
method may differ from that detected by IaaA, the onset and
duration of the UI peak identified in serum by these two
methods might also differ. We therefore compared resultsfor
serum by with those by RIA of serum sampled daily
from normally ovulating women. Such samples were ob-
tained from eight women over 10 ovulatory cyclesbeginning
three to four days before the anticipated UI peak, and UI
was measured by im&A (Immunochem Corp.-Imm 2241) and
by RIA (RSL-124). Both kits are calibrated by the supplier
against WHO 1st IRP 68/40 UI reference preparation. For
42 samples analyzed by both methods, the correlation
coefficient was 0.84. In 10 of 10 cycles the day of the UI
peak, defined as the highest UI value detected, was on the
same day for m and RIA. For the paired samples,
however, mrt measured on average 38% higher than RIA
(P = 0.001).
We conclude: (a) MA may be used as validly as RIA to
identify the serum periovulatory UI peak in daily samples
but (b) serum UI values so obtained are 38% higher than
those obtained by RIA, so clinical users must adjust their
normal UI surge threshold values accordingly.
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